In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci

被引：33

作者：

Livermore, David M. ^{[1
]}

Warner, Marina ^{[1
]}

Mushtaq, Shazad ^{[1
]}

North, Sarah ^{[1
]}

Woodford, Neil ^{[1
]}

机构：

[1] Hlth Protect Agcy, Antibiot Resistance Monitoring & Reference Lab, Ctr Infect, London NW9 5EQ, England

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2007年 / 51卷 / 03期

关键词：

D O I：

10.1128/AAC.01347-06

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to I mu g/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of I or 2 mu g/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 mu g/ml, versus linezolid MICs of 8 to 64 mu g/ml; actual values reflected the proportion of gene copies mutated.

引用

页码：1112 / 1114

页数：3

共 11 条

[1]

[Anonymous], [No title captured]

[2] In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457 [J].

Foleno, Barbara D. ;

Abbanat, Darren ;

Goldschmidt, Raul M. ;

Flamm, Robert K. ;

Paget, Steve D. ;

Webb, Glenda C. ;

Wira, Ellyn ;

Macielag, Mark J. ;

Bush, Karen .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) :361-365

[3] Dominance of EMRSA-15 and-16 among MRSA causing nosocomial bacteraemia in the UK:: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS) -: J Antimicrob Chemother 2001;: 48:143-144 [J].

Johnson, AP ;

Aucken, HM ;

Cavendish, S ;

Ganner, M ;

Wale, MCJ ;

Warner, M ;

Livermore, DM ;

Cookson, BD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (01) :143-144

[4] Linezolid in vitro:: mechanism and antibacterial spectrum [J].

Livermore, DM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :9-16

[5] Antimicrobial resistance to linezolid [J].

Meka, VG ;

Gold, HS .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) :1010-1015

[6] Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low [J].

O'Neill, AJ ;

Chopra, I .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (02) :161-169

[7] Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme [J].

Reynolds, R ;

Potz, N ;

Colman, M ;

Williams, A ;

Livermore, D ;

MacGowan, A .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (06) :1018-1032

[8] Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in enterococci [J].

Sinclair, A ;

Arnold, C ;

Woodford, N .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3620-3622

[9] Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections [J].

Weigelt, J ;

Itani, K ;

Stevens, D ;

Lau, W ;

Dryden, M ;

Knirsch, C .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) :2260-2266

[10] Efficacy of linezolid versus comparator therapies in Gram-positive infections [J].

Wilcox, MH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :27-35

← 1 2 →